Company profile

Health care systems face major financial challenges. We aim to direct our research and development activities toward developing innovative products and renal therapies that not only meet high quality standards that improve clinical outcomes but are also affordable. As an operator of proprietary dialysis clinics and a provider of products for treating patients at home, we believe that these aims are entirely compatible.

Our research and development strategy contributes to our corporate strategy which aims to provide health care for chronically and critically ill patients across the renal care continuum by developing adjacent products and therapies for Extracorporeal Membrane Oxygenation, as well as by acquiring and developing complementary assets. Our globally orientated research and development strategy enables us to respond more effectively to the worldwide rise in demand for high-quality and cost-efficient treatment and therapy methods.

In conjunction with our research and development activities, we collaborate with external partners to expand our comprehensive innovation and technology network. These partners include numerous academic institutions, such as research institutes at prestigious universities in the U.S. In the Renal Research Institute, a subsidiary of Fresenius Medical Care in New York, we have a renowned institution in the field of clinical research into all aspects of chronic kidney failure, working on fundamental issues relating to renal therapies. In addition, Fresenius Medical Care Ventures collaborates with start-ups and early-stage companies in the health care sector with the objective of promoting an open culture of innovation and enabling access to the latest technologies.